Surgical Treatment of Hyperthyroidism – Experience of the Department of Endocrine Surgery, University Clinical Center Kragujevac

  • Slobodan Jakovljevic Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
  • Jovan Pešović Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
  • Duško Nešovanović Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
  • Vladimir Tvrdišić Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
  • Marko University of Kragujevac, Faculty of Medical Sciences, Department of Surgery, Kragujevac, Serbia
  • Borka Milev Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
  • Zlata Juković Clinic of General Surgery, Department of Endocrine Surgery, University Clinical Center Kragujevac, Serbia
DOI: https://doi.org/10.5937/mckg60-64223
Keywords: hyperthyroidism, Graves’ disease, toxic multinodular goiter, toxic adenoma, thyroidectomy, complications

Abstract


Introduction: Hyperthyroidism represents a significant endocrine disorder, with the most common causes being Graves’ disease (GD), toxic multinodular goiter (TMNG), and toxic adenoma (TA). Surgical treatment occupies an important place in the therapeutic algorithm, particularly in situations where medical therapy or radioactive iodine treatment is contraindicated or ineffective.

Objective: To present the experience of the Department of Endocrine Surgery of the University Clinical Center Kragujevac in the surgical treatment of hyperthyroidism during the period 2018–2024.

Materials and Methods: A retrospective analysis was conducted of 188 patients operated on for hyperthyroidism, out of a total of 480 patients who underwent surgery for thyroid diseases over a six-year period. The analyzed parameters included diagnosis type, type of surgical procedure, demographic data, incidence of carcinoma on definitive histopathological findings, and postoperative complications.

Results: Among the 188 operated patients, 62 had GD, 65 had TMNG, and 61 had TA. In patients with GD, total thyroidectomy was performed in 55 cases and near-total thyroidectomy in 7 cases. In the TMNG group, total thyroidectomy was performed in 60 patients and near-total thyroidectomy in 5 patients. In all 61 patients with TA, lobectomy was performed. The mean age was 48.6 years for GD, 58.3 years for TMNG, and 46.5 years for TA. The female-to-male ratio was 5:1 in GD, 4:1 in TMNG, and 4:1 in TA. Thyroid micropapillary carcinoma was detected in 1 patient with GD, 5 patients with TMNG, and 2 patients with TA. Complications included seroma in 8 patients, hematoma in 4 patients, permanent recurrent laryngeal nerve paralysis in 2 patients, transient recurrent laryngeal nerve paralysis in 5 patients, and transient hypocalcemia in 14 patients.

Conclusion: Surgical treatment of hyperthyroidism in our center has demonstrated favorable outcomes with a low rate of serious complications. The results are consistent with contemporary literature and confirm that surgery remains an important therapeutic option in appropriately selected indications.

References

1. Vanderpump MPJ. The epidemiology of thyroid disease. Br Med Bull. 2011;99:39–51.
2. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29(1):76–131.
3. Brent GA. Graves’ disease. N Engl J Med. 2008;358:2594–2605.
4. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906–918.
5. Ross DS, et al. 2016 American Thyroid Association Guidelines. Thyroid. 2016;26(10):1343–1421.
6. Bartalena L, et al. Management of hyperthyroidism. Eur J Endocrinol. 2018;178:R19–R29.
7. Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375:1552–1565.
8. Kahaly GJ, et al. European Thyroid Association guideline. Eur Thyroid J. 2018;7:167–186.
9. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738.
10. Palit TK, et al. The efficacy of thyroidectomy for Graves’ disease. Surgery. 2000;128:1026–1032.
11. Bonnema SJ, Hegedüs L. Management of multinodular toxic goiter. Endocr Rev. 2012;33:676–716.
12. Delbridge L, et al. Total thyroidectomy for benign disease. Br J Surg. 1999;86:1312–1315.
13. Ríos A, et al. Surgical management of multinodular goiter. World J Surg. 2005;29:131–135.
14. Hamburger JI. The autonomously functioning thyroid nodule. Ann Intern Med. 1980;93:1–12.
15. Miccoli P, et al. Surgical treatment of toxic adenoma. Surgery. 1997;121:646–651.
16. Thomusch O, et al. Risk factors for postoperative complications. Br J Surg. 2000;87:168–175.
17. Bergenfelz A, et al. Complications to thyroid surgery. Langenbecks Arch Surg. 2008;393:667–673.
18. Hannan SA. The significance of thyroid surgery volume. Ann R Coll Surg Engl. 2006;88:313–314.
19. Bartalena L, Burch HB, Burman KD, Cooper DS. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016;84(1):115–120.
20. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167–186.
21. Hegedüs L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102–132.
22. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
23. Barczyński M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Nowak W. Randomized clinical trial of total thyroidectomy versus subtotal thyroidectomy for Graves’ disease. Br J Surg. 2012;99(4):515–522.
24. Lang BH, Lo CY. Total thyroidectomy for Graves’ disease: a safe and effective treatment. ANZ J Surg. 2006;76(10):857–860.
25. Erbil Y, Barbaros U, Ozbey N, Kapran Y, Bozbora A, Molvalilar S, et al. Predictive factors for recurrent laryngeal nerve palsy and hypoparathyroidism after thyroid surgery. Clin Otolaryngol. 2007;32(1):32–37.
26. Dionigi G, Bacuzzi A, Bertocchi V, Rovera F, Boni L, Cuffari S, et al. The prevalence of incidental thyroid carcinoma in multinodular goiter. Acta Chir Belg. 2008;108(5):542–546.
27. Miccoli P, Minuto MN, Galleri D, D’Agostino J, Basolo F, Antonangeli L, et al. Incidental thyroid carcinoma in a large series of thyroidectomies for benign disease. Surgery. 2006;140(6):949–956.
28. Kandil E, Krishnan B, Noureldine SI, Yao L, Tufano RP. Hematoma after thyroid surgery: a national perspective. Laryngoscope. 2013;123(1):230–236.
29. Bergenfelz A, Jansson S, Kristoffersson A, Mårtensson H, Reihnér E, Wallin G, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit. Langenbecks Arch Surg. 2008;393(5):667–673.
30. Sitges-Serra A, Ruiz S, Girvent M, Manjón H, Dueñas JP, Sancho JJ. Outcome of protracted hypoparathyroidism after total thyroidectomy. Br J Surg. 2010;97(11):1687–1695.
31. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Complications in thyroid surgery. Minerva Chir. 2007;62(6):395–408.
Published
2026/06/18
Issue
Vol. 60 No. 1 (2026): MEDICINSKI ČASOPIS
Section
Original Scientific Paper